Abbonarsi

Adamalysins in COVID-19 – Potential mechanisms behind exacerbating the disease - 27/05/22

Doi : 10.1016/j.biopha.2022.112970 
Ivo Ricardo de Seabra Rodrigues Dias a, b, Zhijian Cao c, , Hang Fai Kwok a, b,
a Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR 
b Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR 
c State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, Hubei, China 

Co-corresponding author.⁎⁎Corresponding author at: Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR.Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida de UniversidadeTaipaMacau SAR

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

The coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is a current pandemic that has resulted in nearly 250 million cases and over 5 million deaths. While vaccines have been developed to prevent infection, and most COVID-19 cases end up being fairly light, there are severe cases of COVID-19 that may end up in death, even with adequate healthcare treatment. New options to combat this disease’s effects, therefore, could prove to be invaluable in saving lives. Adamalysins are proteins that have several roles in regulating different functions in the human body but are also known to have functions in inflammation. They are also known to have roles in several different diseases, including COVID-19, where ADAM17, in particular, is now well-known to have a prominent role, but also several diseases which include comorbidities that may worsen cases of COVID-19. Therefore, investigating the functions of adamalysins in disease may give us clues to the molecular workings of COVID-19 as well as potentially new therapeutic targets. Understanding these molecular mechanisms may also allow for an understanding of the mechanisms behind the rare severe side effects that occur in response to current COVID-19 vaccines, which may lead to better monitoring measures for people who may be more at risk of developing these side effects. This review investigates the known roles and functions of adamalysins in disease, including what is currently known of their involvement in COVID-19, and how these functions might be involved.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




ga1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

New COVID-19 therapies are still needed, especially for severe cases.
Adamalysins have been found to be involved in COVID-19 pathogenesis.
Known adamalysins involved include ADAM17, ADAM12 and ADAMTS13.
They play roles in virus entry into cells, inflammation, fibrosis, thrombosis, etc.
Other adamalysins that contribute to similar pathogenesis could also be involved in COVID-19.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : SARS-CoV-2, COVID-19, Inflammation, ADAM, ADAMTS, ADAMTSL


Mappa


© 2022  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 150

Articolo 112970- Giugno 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Association between P2X3 receptors and neuropathic pain: As a potential therapeutic target for therapy
  • Cai-rong Dong, Wen-jun Zhang, Hong-liang Luo
| Articolo seguente Articolo seguente
  • Urinary exosomes: Emerging therapy delivery tools and biomarkers for urinary system diseases
  • Xin Li, Lina Yang

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.